(Q39943302)

15 September 2017

title

Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma (English)

1 reference

15 September 2017

1 reference

1 reference

13

1 reference

15 September 2017

6

Takaomi Sanda

1 reference

15 September 2017

Hiroki Yano

1

1 reference

15 September 2017

Satoshi Kayukawa

2

1 reference

15 September 2017

Shinsuke Iida

3

1 reference

15 September 2017

Chiharu Nakagawa

4

1 reference

15 September 2017

Tetsuya Oguri

5

1 reference

15 September 2017

Jianming Ding

7

1 reference

15 September 2017

Fumiko Mori

8

1 reference

15 September 2017

Asahi Ito

9

1 reference

15 September 2017

Masaki Ri

10

1 reference

15 September 2017

Atsushi Inagaki

11

1 reference

15 September 2017

Shigeru Kusumoto

12

1 reference

15 September 2017

Hirokazu Komatsu

14

1 reference

15 September 2017

Hiroshi Inagaki

15

1 reference

15 September 2017

Atsushi Suzuki

16

1 reference

15 September 2017

Ryuzo Ueda

17

1 reference

15 September 2017

publication date

1 September 2008

1 reference

15 September 2017

1 reference

15 September 2017

volume

99

1 reference

15 September 2017

issue

11

1 reference

15 September 2017

page(s)

2309-2314

1 reference

Multistep Tumorigenesis of Multiple Myeloma: Its Molecular Delineation

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00936.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00936.X

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00936.X

Multiple myeloma cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00936.X

Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00936.X

ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00936.X

The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00936.X

Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00936.X

Pharmacogenetics of irinotecan metabolism and transport: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00936.X

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00936.X

Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00936.X

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00936.X

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00936.X

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00936.X

Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00936.X

Serum free light chains for monitoring multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00936.X

Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2008.00936.X

10.1111/J.1349-7006.2008.00936.X

21 January 2018

Identifiers

DOI

1 reference

15 September 2017

1 reference